SEARCH

SEARCH BY CITATION

References

  • 1
    Tomita M, Shimizu T, Ayabe T, Onitsuka T. Maximum SUV on positron emission tomography and serum CEA level as prognostic factors after curative resection for non-small cell lung cancer. Asia-Pac J Clin Oncol 2012; 8: 244247.
  • 2
    Isobe K, Hata Y, Sakaguchi S et al. Pathological response and prognosis of stage III non-small cell lung cancer patients treated with induction chemoradiation. Asia-Pac J Clin Oncol 2012; 8: 260266.
  • 3
    Cerfolio RJ, Bryant AS, Winokur TS, Ohja B, Bartolucci AA. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004; 78:19031909; discussion 9.
  • 4
    Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. NEJM 2009; 361: 947957.
  • 5
    Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12:735742.
  • 6
    Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239246.
  • 7
    Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121128.
  • 8
    Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. NEJM 2010; 362: 23802388.
  • 9
    Wu YL, Chu DT, Han B et al. Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. Asia-Pac J Clin Oncol 2012; 8: 232243.
  • 10
    Liam CK, Ruthranesan M, Lee CH, Pang YK, Chua KT, Lim BK. Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib. Asia-Pac J Clin Oncol 2012; 8: 267274.
  • 11
    Boyer M, Horwood K, Pavlakis N et al. Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study. Asia-Pac J Clin Oncol 2012; 8: 248254.